Drug Trial Radar · NCT00736099
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,122
Actual
Start
Aug 2008
Primary completion
Dec 2010
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Aug 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 82 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment. The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)
Conditions
- Diabetes Mellitus, Type 2
Interventions
linagliptine 5 mgDrug
safety and efficacy of linagliptine 5 mg open label
linagliptine 5 mg and pioglitazone 30 mgDrug
efficacy and safety of the combination linagliptine and pioglitazone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Patients With Adverse Events (AEs)Time frame: 78 weeks
- Frequency of Patients With Investigator-defined Hypoglycaemic Adverse EventsTime frame: 78 weeks
- Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ)Time frame: 78 weeks
- Frequency of Patients With Adjudication of Cardiac and Cerebrovascular EventsTime frame: 78 weeks
- Number of Patients With Abnormalities in Vital SignsTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: EosinophilsTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: HaemoglobinTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: HaematocritTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: Red Blood Cell CountTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: White Blood Cell CountTime frame: 78 weeks
- Number of Patients With Abnormalities in Haematology: PlateletsTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: PotassiumTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Uric AcidTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: TriglyceridesTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: AmylaseTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT)Time frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: CreatinineTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Creatinine KinaseTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: PhosphateTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: CalciumTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: SodiumTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT)Time frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST)Time frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: GlucoseTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: BilirubinTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP)Time frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: AlbuminTime frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH)Time frame: 78 weeks
- Number of Patients With Abnormalities in Clinical Chemistry: CholesterolTime frame: 78 weeks
Locations
232 sites in 32 countries. Site status is shown where the registry gives one.
1218.40.10003 Boehringer Ingelheim Investigational Site
Chula Vista, California
1218.40.10014 Boehringer Ingelheim Investigational Site
Spring Valley, California
1218.40.10001 Boehringer Ingelheim Investigational Site
Walnut Creek, California
1218.40.10021 Boehringer Ingelheim Investigational Site
Northglenn, Colorado
1218.40.10010 Boehringer Ingelheim Investigational Site
Hollywood, Florida
1218.40.10011 Boehringer Ingelheim Investigational Site
Miami, Florida
1218.40.10016 Boehringer Ingelheim Investigational Site
Eugene, Oregon
1218.40.10002 Boehringer Ingelheim Investigational Site
Greer, South Carolina
1218.40.10004 Boehringer Ingelheim Investigational Site
Simpsonville, South Carolina
1218.40.10005 Boehringer Ingelheim Investigational Site
Dallas, Texas
1218.40.10018 Boehringer Ingelheim Investigational Site
Houston, Texas
1218.40.10007 Boehringer Ingelheim Investigational Site
San Antonio, Texas
1218.40.10009 Boehringer Ingelheim Investigational Site
Federal Way, Washington
1218.40.54002 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.40.54010 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1218.40.54011 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
1218.40.54015 Boehringer Ingelheim Investigational Site
Parque Velez Sarfield, Argentina
1218.40.43001 Boehringer Ingelheim Investigational Site
Graz, Austria
1218.40.43005 Boehringer Ingelheim Investigational Site
Vienna, Austria
1218.40.32005 Boehringer Ingelheim Investigational Site
Bruges, Belgium
1218.40.32007 Boehringer Ingelheim Investigational Site
Brussels, Belgium
1218.40.32006 Boehringer Ingelheim Investigational Site
Edegem, Belgium
1218.40.32004 Boehringer Ingelheim Investigational Site
Genk, Belgium
1218.40.32003 Boehringer Ingelheim Investigational Site
Ghent, Belgium
1218.40.32002 Boehringer Ingelheim Investigational Site
Huy, Belgium
1218.40.32001 Boehringer Ingelheim Investigational Site
Liège, Belgium
1218.40.01005 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1218.40.01010 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1218.40.01003 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.40.01011 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.40.01006 Boehringer Ingelheim Investigational Site
Etobicoke, Ontario, Canada
1218.40.01009 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1218.40.01002 Boehringer Ingelheim Investigational Site
London, Ontario, Canada
1218.40.01012 Boehringer Ingelheim Investigational Site
Oakville, Ontario, Canada
1218.40.01008 Boehringer Ingelheim Investigational Site
Sarnia, Ontario, Canada
1218.40.20005 Boehringer Ingelheim Investigational Site
Strathroy, Ontario, Canada
1218.40.01001 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1218.40.01004 Boehringer Ingelheim Investigational Site
Montague, Prince Edward Island, Canada
1218.40.01007 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1218.40.86001 Boehringer Ingelheim Investigational Site
Beijing, China
Showing 40 of 232 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.